Clinical Trial Update: Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of saracatinib for locally advanced or metastatic stomach/ gastroesophageal junction cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Adenocarcinoma of the Stomach

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach | Phase 2 | Status: COMPLETED | Results posted: 2014-07-18